These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 7907906)
21. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
22. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877 [TBL] [Abstract][Full Text] [Related]
23. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
24. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161 [TBL] [Abstract][Full Text] [Related]
25. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
26. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. van Besien K; Margolin K; Champlin R; Forman S Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395 [TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas. Mabed M; Al-Kgodary T Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587 [TBL] [Abstract][Full Text] [Related]
28. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752 [TBL] [Abstract][Full Text] [Related]
29. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Weaver CH; Schwartzberg L; Li W; Hazelton B; West W Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687 [TBL] [Abstract][Full Text] [Related]
31. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Vose JM Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446 [TBL] [Abstract][Full Text] [Related]
32. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650 [TBL] [Abstract][Full Text] [Related]
33. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678 [TBL] [Abstract][Full Text] [Related]
34. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183 [TBL] [Abstract][Full Text] [Related]
35. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Tarella C; Caracciolo D; Gavarotti P; Bondesan P; Cherasco C; Omedè P; Bregni M; Siena S; Gianni AM; Pileri A Bone Marrow Transplant; 1995 Aug; 16(2):223-8. PubMed ID: 7581140 [TBL] [Abstract][Full Text] [Related]
36. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma. Moreau P; LeTortorec S; Mahé MA; Mahé B; Moreau A; Bourdin S; Bulabois CE; Bureau B; Harousseau JL; Milpied N Bone Marrow Transplant; 1994 Nov; 14(5):775-8. PubMed ID: 7889011 [TBL] [Abstract][Full Text] [Related]
37. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features. Baro J; Richard C; Calavia J; González-San Miguel JD; Bello-Fernández C; Alsar MJ; Gómez-Casares MT; Iriondo A; Conde E; Hermosa V Bone Marrow Transplant; 1991 Oct; 8(4):283-9. PubMed ID: 1756325 [TBL] [Abstract][Full Text] [Related]
38. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261 [TBL] [Abstract][Full Text] [Related]
39. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma. Armitage JO; Gingrich RD; Klassen LW; Bierman PJ; Kumar PP; Weisenburger DD; Smith DM Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847 [TBL] [Abstract][Full Text] [Related]
40. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas. Ghalie R; Richman CM; Adler SS; Korenblit AD; Kramer TS; Manson S; Dolce A; Kaizer H Bone Marrow Transplant; 1991 Jul; 8(1):41-5. PubMed ID: 1912954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]